肝胆相照论坛

标题: [必须阅读]Virological breakthrough and resistance in patients with chronic h [打印本页]

作者: StephenW 时间: 2011-3-30 20:56 标题: [必须阅读]Virological breakthrough and resistance in patients with chronic h

本帖最后由风雨不动于 2012-4-14 15:28 编辑

<http://onlinelibrary.wiley.com/doi/10.1002/hep.24318/abstract?systemMessage=Wiley>+Online+Library+will+be+disrupted+2nd+Apr+from+10-12+BST+for+monthly+maintenance

Viral Hepatitis
Virological breakthrough and resistance in patients with chronic hepatitis
B receiving nucleos(t)ide analogs in clinical practice

Chanunta Hongthanakorn, Watcharasak Chotiyaputta, Kelly Oberhelman, Robert
J. Fontana, Jorge A. Marrero, Tracy Licari, Anna S.F. Lok,†DOI:

10.1002/hep.24318
Copyright © 2011 American Association for the Study of Liver Diseases
Issue

Hepatology
Accepted Article (Accepted, unedited articles published online for future
issues)

Abstract
Virological breakthrough (VBT) is the first manifestation of antiviral drug
resistance during nucleos(t)ide analog (NUC) treatment of chronic hepatitis
B (CHB) but not all VBTs are due to drug resistance. The aims of this study
were to determine the incidence of virological breakthrough (VBT) and
genotypic resistance (GR) in CHB patients receiving NUCs in clinical
practice. Records of CHB patients receiving NUCs were reviewed. All
patients with VBT were tested for drug resistance mutations. Of 148
patients included, 73% were men, mean age was 44.9 years. During a mean
follow-up of 37.5±20.1 months, 39 (26%) patients had at least 1 VBT. Of
these 39 patients, 15 (38%) were not confirmed to have VBT on retesting and
10 of these 15 had no evidence of GR. The cumulative probability of VBT,
confirmed VBT, and GR at 5 years was 46.1%, 29.7%, and 33.9%, respectively.
In multivariate analysis, failure to achieve undetectable HBV DNA was the
only factor significantly associated with VBT. Among the 10 patients who
had VBT but no confirmed VBT or GR and who were maintained on the same
medications, serum HBV DNA decreased in all 10 and 9 had undetectable HBV
DNA a mean of 6.8 months after the VBT. Four patients had persistently
undetectable HBV DNA while six had transient increase in HBV DNA during
follow-up but none had GR.

Conclusion: VBT was common in CHB patients receiving NUCs in clinical
practice, but nearly 40% of the VBTs were not related to antiviral drug
resistance. Counseling of CHB patients on medication adherence and
confirmation of VBT and/or GR can avoid unnecessary changes in antiviral
medications.

(HEPATOLOGY 2011.)

(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

作者: 走遍四方 时间: 2011-3-31 11:41

yes, got it :

作者: kennyu 时间: 2011-3-31 13:31

回复 StephenW 的帖子

我曾经看到过替诺福韦的实验数据，有的病人，并不发生耐药，但是会出现VBT
当时感觉很奇怪，现在看，其实没啥。
过段时间说不定DNA还会回去。

作者: interdetect 时间: 2011-3-31 13:50

没说明人种

作者: interdetect 时间: 2011-3-31 13:54

病例数太少不太能说明问题

作者: StephenW 时间: 2011-3-31 14:21

kennyu 发表于 2011-3-31 13:31
回复 StephenW 的帖子

我曾经看到过替诺福韦的实验数据，有的病人，并不发生耐药，但是会出现VBT

乙型肝炎病毒是真是复杂. 最重要的信息, 不要过急改变医疗药.

作者: StephenW 时间: 2011-3-31 14:24

interdetect 发表于 2011-3-31 13:54
病例数太少不太能说明问题

当然, 需要阅读整个文章. Anna S.F. Lok 在美国顶尖.

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)